Antipodean Advisors’s Aptose Biosciences, Inc. APTO Stock Holding History

Antipodean Advisors’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-56	Closed	-$48K	–	10
2018 Q4	$48K	Hold	56	–	–	0.09%	7
2018 Q3	$65K	Hold	56	–	–	0.08%	11
2018 Q2	$99K	Hold	56	–	–	0.12%	9
2018 Q1	$79K	Buy	+56	New	+$74.9K	0.09%	13

Other funds holding APTO

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

NFG

Noven Financial Group Denver, Colorado $123M AUM 5.23% 1-Year Est. Return

Antipodean Advisors's APTO Position: Q1 2019 in Review

Antipodean Advisors sold out of Aptose Biosciences, Inc. (APTO) in Q1 2019, closing a stake of 56 shares — an estimated $48K sold.

Antipodean Advisors first reported a position in APTO in Q1 2018 and held it in 4 quarters. The position peaked at $99K in Q2 2018. 22 funds tracked by Wall St. Rank hold APTO as of Q1 2019.

Antipodean Advisors reported no remaining Aptose Biosciences, Inc. position as of Q1 2019 after selling out during the quarter.
Antipodean Advisors sold 56 Aptose Biosciences, Inc. shares in Q1 2019, an estimated $48K.
Antipodean Advisors first reported a position in Aptose Biosciences, Inc. in Q1 2018 and held it in 4 quarters.
Antipodean Advisors's Aptose Biosciences, Inc. position peaked at $99K in Q2 2018.
22 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q1 2019.

Based on Antipodean Advisors's 13F filing for Q1 2019, filed 15 May 2019.